A postmarketing surveillance program to monitor Ultram® (tramadol hydrochloride) abuse in the United States

Theodore J. Cicero, Edgar H. Adams, Anne Geller, James A. Inciardi, Alvaro Munoz, Sidney H. Schnoll, Edward C. Senay, George E. Woody

Research output: Contribution to journalArticle

Abstract

Tramadol HCl, marketed as Ultram® in the USA, was introduced as a non-scheduled drug in April 1995 based on the assumption that the risk of abuse was sufficiently low to warrant a non-scheduled status. However, approval was contingent upon the development of an innovative proactive surveillance program, to be overseen by an independent steering committee, which would detect unexpectedly high levels of abuse. The postmarketing surveillance program consisted of systematic collection and scientific evaluation of reports of suspected abuse in high-risk populations surveyed through an extensive key informant network of drug abuse specialists and all spontaneous reports of abuse received through the FDA MedWatch system. Methods to estimate the number of patients prescribed tramadol were also developed. Monthly rates of abuse were calculated as an index of the risk-benefit ratio (i.e., abuse cases per 100 000 patients prescribed the drug). The data for the 3 years since the drug was introduced show that the reported rate of abuse has been low. Although a period of experimentation seemed to occur in the first 18 months after its introduction-which reached a peak rate of approximately two cases per 100 000 patients exposed-during the 2 year period prior to June 1998, the reported rate of abuse has significantly (P=0.011) declined, reaching levels of less than one case per 100 000 patients in the last 18 months. The overwhelming majority of abuse cases (97%) have been found to occur among individuals with a history of substance abuse and the abuse has been confined to isolated pockets around the country-notably none of which have significant populations of street drug abusers. Thus, the data support the decision not to schedule tramadol and, furthermore, suggest that a proactive post-marketing surveillance program can be successfully developed to effectively monitor abuse of new medications. Copyright (C) 1999 Elsevier Science Ireland Ltd.

Original languageEnglish (US)
Pages (from-to)7-22
Number of pages16
JournalDrug and Alcohol Dependence
Volume57
Issue number1
DOIs
StatePublished - Nov 1 1999

Fingerprint

Tramadol
surveillance
abuse
Pharmaceutical Preparations
Substance-Related Disorders
Street Drugs
Drug Users
Marketing
drug
Population
Appointments and Schedules
Odds Ratio
drug abuse
substance abuse
medication
marketing

Keywords

  • Controlled Substances Act
  • Drug abuse
  • Drug dependence
  • Postmarketing surveillance
  • Tramadol HCl
  • Ultram®

ASJC Scopus subject areas

  • Medicine(all)
  • Behavioral Neuroscience
  • Toxicology
  • Health(social science)

Cite this

A postmarketing surveillance program to monitor Ultram® (tramadol hydrochloride) abuse in the United States. / Cicero, Theodore J.; Adams, Edgar H.; Geller, Anne; Inciardi, James A.; Munoz, Alvaro; Schnoll, Sidney H.; Senay, Edward C.; Woody, George E.

In: Drug and Alcohol Dependence, Vol. 57, No. 1, 01.11.1999, p. 7-22.

Research output: Contribution to journalArticle

Cicero, Theodore J. ; Adams, Edgar H. ; Geller, Anne ; Inciardi, James A. ; Munoz, Alvaro ; Schnoll, Sidney H. ; Senay, Edward C. ; Woody, George E. / A postmarketing surveillance program to monitor Ultram® (tramadol hydrochloride) abuse in the United States. In: Drug and Alcohol Dependence. 1999 ; Vol. 57, No. 1. pp. 7-22.
@article{23f86182ab4a4fcdbc1ea59dbf6b3978,
title = "A postmarketing surveillance program to monitor Ultram{\circledR} (tramadol hydrochloride) abuse in the United States",
abstract = "Tramadol HCl, marketed as Ultram{\circledR} in the USA, was introduced as a non-scheduled drug in April 1995 based on the assumption that the risk of abuse was sufficiently low to warrant a non-scheduled status. However, approval was contingent upon the development of an innovative proactive surveillance program, to be overseen by an independent steering committee, which would detect unexpectedly high levels of abuse. The postmarketing surveillance program consisted of systematic collection and scientific evaluation of reports of suspected abuse in high-risk populations surveyed through an extensive key informant network of drug abuse specialists and all spontaneous reports of abuse received through the FDA MedWatch system. Methods to estimate the number of patients prescribed tramadol were also developed. Monthly rates of abuse were calculated as an index of the risk-benefit ratio (i.e., abuse cases per 100 000 patients prescribed the drug). The data for the 3 years since the drug was introduced show that the reported rate of abuse has been low. Although a period of experimentation seemed to occur in the first 18 months after its introduction-which reached a peak rate of approximately two cases per 100 000 patients exposed-during the 2 year period prior to June 1998, the reported rate of abuse has significantly (P=0.011) declined, reaching levels of less than one case per 100 000 patients in the last 18 months. The overwhelming majority of abuse cases (97{\%}) have been found to occur among individuals with a history of substance abuse and the abuse has been confined to isolated pockets around the country-notably none of which have significant populations of street drug abusers. Thus, the data support the decision not to schedule tramadol and, furthermore, suggest that a proactive post-marketing surveillance program can be successfully developed to effectively monitor abuse of new medications. Copyright (C) 1999 Elsevier Science Ireland Ltd.",
keywords = "Controlled Substances Act, Drug abuse, Drug dependence, Postmarketing surveillance, Tramadol HCl, Ultram{\circledR}",
author = "Cicero, {Theodore J.} and Adams, {Edgar H.} and Anne Geller and Inciardi, {James A.} and Alvaro Munoz and Schnoll, {Sidney H.} and Senay, {Edward C.} and Woody, {George E.}",
year = "1999",
month = "11",
day = "1",
doi = "10.1016/S0376-8716(99)00041-1",
language = "English (US)",
volume = "57",
pages = "7--22",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - A postmarketing surveillance program to monitor Ultram® (tramadol hydrochloride) abuse in the United States

AU - Cicero, Theodore J.

AU - Adams, Edgar H.

AU - Geller, Anne

AU - Inciardi, James A.

AU - Munoz, Alvaro

AU - Schnoll, Sidney H.

AU - Senay, Edward C.

AU - Woody, George E.

PY - 1999/11/1

Y1 - 1999/11/1

N2 - Tramadol HCl, marketed as Ultram® in the USA, was introduced as a non-scheduled drug in April 1995 based on the assumption that the risk of abuse was sufficiently low to warrant a non-scheduled status. However, approval was contingent upon the development of an innovative proactive surveillance program, to be overseen by an independent steering committee, which would detect unexpectedly high levels of abuse. The postmarketing surveillance program consisted of systematic collection and scientific evaluation of reports of suspected abuse in high-risk populations surveyed through an extensive key informant network of drug abuse specialists and all spontaneous reports of abuse received through the FDA MedWatch system. Methods to estimate the number of patients prescribed tramadol were also developed. Monthly rates of abuse were calculated as an index of the risk-benefit ratio (i.e., abuse cases per 100 000 patients prescribed the drug). The data for the 3 years since the drug was introduced show that the reported rate of abuse has been low. Although a period of experimentation seemed to occur in the first 18 months after its introduction-which reached a peak rate of approximately two cases per 100 000 patients exposed-during the 2 year period prior to June 1998, the reported rate of abuse has significantly (P=0.011) declined, reaching levels of less than one case per 100 000 patients in the last 18 months. The overwhelming majority of abuse cases (97%) have been found to occur among individuals with a history of substance abuse and the abuse has been confined to isolated pockets around the country-notably none of which have significant populations of street drug abusers. Thus, the data support the decision not to schedule tramadol and, furthermore, suggest that a proactive post-marketing surveillance program can be successfully developed to effectively monitor abuse of new medications. Copyright (C) 1999 Elsevier Science Ireland Ltd.

AB - Tramadol HCl, marketed as Ultram® in the USA, was introduced as a non-scheduled drug in April 1995 based on the assumption that the risk of abuse was sufficiently low to warrant a non-scheduled status. However, approval was contingent upon the development of an innovative proactive surveillance program, to be overseen by an independent steering committee, which would detect unexpectedly high levels of abuse. The postmarketing surveillance program consisted of systematic collection and scientific evaluation of reports of suspected abuse in high-risk populations surveyed through an extensive key informant network of drug abuse specialists and all spontaneous reports of abuse received through the FDA MedWatch system. Methods to estimate the number of patients prescribed tramadol were also developed. Monthly rates of abuse were calculated as an index of the risk-benefit ratio (i.e., abuse cases per 100 000 patients prescribed the drug). The data for the 3 years since the drug was introduced show that the reported rate of abuse has been low. Although a period of experimentation seemed to occur in the first 18 months after its introduction-which reached a peak rate of approximately two cases per 100 000 patients exposed-during the 2 year period prior to June 1998, the reported rate of abuse has significantly (P=0.011) declined, reaching levels of less than one case per 100 000 patients in the last 18 months. The overwhelming majority of abuse cases (97%) have been found to occur among individuals with a history of substance abuse and the abuse has been confined to isolated pockets around the country-notably none of which have significant populations of street drug abusers. Thus, the data support the decision not to schedule tramadol and, furthermore, suggest that a proactive post-marketing surveillance program can be successfully developed to effectively monitor abuse of new medications. Copyright (C) 1999 Elsevier Science Ireland Ltd.

KW - Controlled Substances Act

KW - Drug abuse

KW - Drug dependence

KW - Postmarketing surveillance

KW - Tramadol HCl

KW - Ultram®

UR - http://www.scopus.com/inward/record.url?scp=0032824204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032824204&partnerID=8YFLogxK

U2 - 10.1016/S0376-8716(99)00041-1

DO - 10.1016/S0376-8716(99)00041-1

M3 - Article

C2 - 10617309

AN - SCOPUS:0032824204

VL - 57

SP - 7

EP - 22

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 1

ER -